Genetic Heterogeneity of Clinically Defined AD. Andrew J. Saykin, PsyD Indiana ADC ADC Clinical Core Leaders Meeting April 22, 2017
|
|
- Kerry Anthony
- 5 years ago
- Views:
Transcription
1 Genetic Heterogeneity of Clinically Defined AD Andrew J. Saykin, PsyD Indiana ADC ADC Clinical Core Leaders Meeting April 22, 2017
2 Disclosures & Acknowledgements Disclosures Eli Lilly (Collaborative Grant), Arkley BioTek (SBIR), Avid Radiopharmaceuticals, GSK Editor-in-Chief, Brain Imaging and Behavior, a Springer Nature journal Grant Support National Institute on Aging P30 AG10133 (IADC) ADNI: U01 AG & RC2 AG036535; Indiana: R01 AG19771 U01 AG032984, U24 AG21886, P30 AG010129, K01 AG National Institute of Biomedical Imaging and Bioengineering National Library of Medicine: R01 LM and K99/R00 LM National Science Foundation: IIS Foundation for the NIH (ADNI-1 GWAS) Anonymous Foundation (Challenge Grant), Gene Network Sciences, Merck, Pfizer ADNI methylation project (AbbVie, Biogen and J&J, in-kind support) Alzheimer s Association & Brin Wojcicki Foundation Whole Genome Sequencing The Indiana Neurorepository Project IUSM Strategic Research Initiative (SRI), Indiana Spinal Cord and Brain Injury Research Fund, CTSI
3 Overview Dimensions of Heterogeneity Genes and gene pathways Impact on risk/protective factors Influence on age of onset Cognitive subtypes and trajectories Signal or noise? Can we model heterogeneity? Implications
4 High Dimensionality Landscape Subjective Cognitive Decline Informant Perception Cognitive Performance Social Networks Lifestyle & environment - Cognitive stimulation, diet, exercise, sleep Biomarkers - CSF, blood, others - Multi-omics Genomics - DNA, mrna, mirna - Epigenetics Amyloid - PET/CSF Tau - PET/CSF MRI - structure MRI - function Connectome Vascular function & CVD burden Immune System, Inflammation & Oxidative Stress Metabolism & Mitochondria Saykin 2017
5 Dynamic Aspects: Temporal Heterogeneity
6 PS2 Heritability LOAD: genetic factors account for ~60-80% of risk (Gatz et al 2006); APOE accounts for up to 50% (Ashford & Mortimer 2002); so up to 30% remains to be found. APOE PS1 Chromosome 19 APP 21q21.3 Chromosome 1 Chromosome 14 Chromosome 21
7 Genetic Risk for AD: Many Pathways C. Karch & A. Goate, Biol Psychiatry 2015; 77:43 51
8 AD Cognitive Subtypes: Studies by Many Groups N. Scheltens et al Alz & Dem 4/2017
9 Cognitive Subtypes N. Scheltens et al Alz & Dem 4/2017
10 Multiple tests and cohorts N. Scheltens et al Alz & Dem 4/2017
11 Genetic architecture of memory and executive functioning in AD (P Crane R01 AG )
12 Subtypes are Heritable (0.68) (P Crane R01 AG )
13 Dynamic Aspects: Cognitive Trajectory
14 Genetics of Resilience Searching for protective factors
15 Cognitively-defined subgroups (P Crane R01 AG )) NACC Data Next Memory most common overall, followed by language Isolated substantial language deficits quite marked in MAP and especially ROS Too few with isolated substantial executive functioning deficits for genetic analyses Multiple domains more common in MAP (especially) and ROS than in ADNI or ACT
16 APOE: Proportion with 1 ε4 alleles Paul Crane et al, unpublished data
17 Genetics of Subtypes: IGAP SNP Results Gene MAF OR ACT ROS/MAP ADNI Meta P(Meta) P(Hetero) SORL1* BIN CR CLU* ABCA PICALM* FERMT CASS4* MS4A6A* EPHA1* HLA-DRB5-HLA-DRB PTK2B CD2AP ZCWPW1* SLC24A4-RIN3* INPP5D CELF NME MEF2C* CD33* Case Control Paul Crane et al, unpublished data
18 No domain with prominent deficits Gene MAF OR ACT ROS/MAP ADNI Meta P(Meta) P(Het) SORL1* BIN CR CLU* ABCA PICALM* FERMT CASS4* MS4A6A* EPHA1* HLA-DRB5-HLA-DRB PTK2B CD2AP ZCWPW1* SLC24A4-RIN3* INPP5D CELF NME MEF2C* CD33* Case Control Paul Crane et al, unpublished data
19 Isolated substantial memory deficits Gene MAF OR ACT ROS/MAP ADNI Meta P(Meta) P(Hetero) SORL1* BIN CR CLU* ABCA PICALM* FERMT CASS4* MS4A6A* EPHA1* HLA-DRB5-HLA-DRB PTK2B CD2AP ZCWPW1* SLC24A4-RIN3* INPP5D CELF NME MEF2C* CD33* Case Control Paul Crane et al, unpublished data
20 Isolated substantial language impairment Gene MAF OR ACT ROS/MAP ADNI Meta P(Meta) P(Het) SORL1* BIN CR < CLU* ABCA PICALM* FERMT CASS4* MS4A6A* EPHA1* HLA-DRB5-HLA-DRB PTK2B CD2AP ZCWPW1* SLC24A4-RIN3* INPP5D CELF NME MEF2C* CD33* Case Control Paul Crane et al, unpublished data
21 Isolated substantial visuospatial impairment Gene MAF OR ACT ROS/MAP ADNI Meta P(Meta) P(Het) SORL1* BIN CR CLU* ABCA PICALM* FERMT CASS4* MS4A6A* EPHA1* HLA-DRB5-HLA-DRB PTK2B CD2AP ZCWPW1* SLC24A4-RIN3* INPP5D CELF NME MEF2C* CD33* Case Control Paul Crane et al, unpublished data
22 Summary of genetic results (meta-analysis) Gene MAF OR No Domain Memory Visuospatial Language SORL1* BIN CR CLU* ABCA PICALM* FERMT CASS4* MS4A6A* * EPHA1* HLA-DRB5-HLA-DRB PTK2B CD2AP * ZCWPW1* SLC24A4-RIN3* INPP5D CELF NME MEF2C* CD33* Case Control Paul Crane et al, unpublished data * Het p<0.05
23 More Heterogeneity: Genetics of Quantitative Endophenotypes: Publications Using ADNI Genetic Data ( ) Year Pubs Shen et al, Brain Imaging Behav 2014; Yao et al, AAIC 2015 & AAIC 2016 & AAIC 2017; Saykin et al, Alzheimers Dement 2015 Updated: 4/2017
24 Role for Polygenic Risk Scores Mormino, E.C., et al., Polygenic risk of Alzheimer disease is associated with early- and late-life processes. Neurology, (5): p Hohman, T.J., et al., Discovery of gene-gene interactions across multiple independent data sets of late onset Alzheimer disease from the Alzheimer Disease Genetics Consortium. Neurobiol Aging, : p Gaiteri, C., et al., Genetic variants in Alzheimer disease - molecular and brain network approaches. Nat Rev Neurol, (7): p Yokoyama, J.S., et al., Decision tree analysis of genetic risk for clinically heterogeneous Alzheimer's disease. BMC Neurol, : p. 47. Martiskainen, H., et al., Effects of Alzheimer's disease-associated risk loci on cerebrospinal fluid biomarkers and disease progression: a polygenic risk score approach. J Alzheimers Dis, (2): p Escott-Price, V., et al., Common polygenic variation enhances risk prediction for Alzheimer's disease. Brain, (Pt 12): p Desikan, R.S., et al., Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score. PLoS Med, (3): p. e
25 Working toward a Systems Biology of AD Saykin et al, Alzheimer s & Dementia 11 (2015)
26 From Noise to Signal: Modeling Heterogeneity Interacting Domains Biomarkers Moderators Outcomes Baseline Cognitive Status Neural Activity & Connectivity Amyloid Burden Tau Burden Microvascular Pathology Neurodegeneration Inflammation & Related Processes Report & Testing Task & RS fmri PET & CSF PET & CSF WMHI, MH, CBF MRI & DTI Fluid Biomarkers - Age - Education - Sex - Genetics - APOE, other - Family Hx - Reserve - Brain - Cognitive - Lifestyle - Exercise - Cognitive - Diet - Environment - Medications Longitudinal Progression: Cognitive Changes Clinical Status MRI & Biomarker Changes * WMHI: white matter hyperintensities; MH: microhemorrhages; CBF: cerebral blood flow
27 IDEAS CMS coverage for amyloid imaging with Evidence Development Trial sponsored by the Alzheimer s Association Managed by the American College of Radiology (ACR) and American College of Radiology Imaging Network (ACRIN) 18,500 patients with cognitive impairment & unclear diagnosis IU site (Apostolova) Genetics add-on study led by IU (Foroud & Saykin) Remote consent and saliva kits for DNA (NCRAD) & Analyses (Imaging Genomics Lab)
28 Relevance for Interventions Cummings et al, Alzheimer s & Dementia: Translational Research & Clinical Interventions 2 (2016)
29 Summary & Discussion Heterogeneity is multidimensional with several axes clinical, neuropathological & genetic Memory prominent APOE+ canonical AD pathology Heterogeneity is dynamic time is another dimension Phenotypes; gene expression, epigenetic modifications, etc. Hopefully we can turn noise into signal -> modeling Understand fundamental disease mechanisms and Tailor therapeutics with real precision How can the ADCs best contribute to resolving issues of heterogeneity?
Indiana University School of Medicine, Indianapolis, IN USA 1
GWAS and Candidate Studies of MRI and Amyloid PET Phenotypes for Alzheimer's Disease Andrew J. Saykin Depts. of Radiology & Imaging Sciences and Medical & Molecular Genetics, Neurology & Psychiatry; Indiana
More informationAlzheimer s Disease Genetics Consortium ADGC. Alzheimer s Disease Sequencing Project ADSP
Alzheimer s Disease Genetics Consortium ADGC Alzheimer s Disease Sequencing Project ADSP National Institute on Aging Genetics of Alzheimer s Disease Storage site NIAGADS Partners: National Alzheimer Coordinating
More informationMedical Policy. MP Genetic Testing for Alzheimer Disease
Medical Policy MP 2.04.13 BCBSA Ref. Policy: 2.04.13 Last Review: 04/30/2018 Effective Date: 4/30/2018 Section: Medicine Related Policies 2.04.14 Biochemical Markers of Alzheimer Disease 6.01.55 β-amyloid
More information25 th Annual Southern California Alzheimer s Disease Research Conference
25 th Annual Southern California Alzheimer s Disease Research Conference New Guidelines and Importance of Brain Donation Thomas J. Montine, MD, PhD Alvord Professor & Chair Department of Pathology University
More informationRoche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment
Roche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment Sunday 2 September 2018 Location: Shanghai, China NP/AZD/1807/0003 Complex
More informationMild Cognitive Impairment Symposium January 19 and 20, 2013
Highlights of Biomarker and Clinical Outcomes in Recent AD Treatment Trials Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University Mild Cognitive Impairment
More informationMoving Targets: An Update on Diagnosing Dementia in the Clinic
Moving Targets: An Update on Diagnosing Dementia in the Clinic Eric McDade DO Department of Neurology School of Medicine Alzheimer Disease Research Center Disclosures No relevant financial disclosures
More informationChapter 1 INTRODUCTION
Chapter 1 INTRODUCTION 7 CHAPTER 1 INTRODUCTION Mr. J., 56 years of age, presents at the VUmc Alzheimer center with progressive word-finding difficulties. The problems had started three years ago during
More informationPolicy #: 011 Latest Review Date: May 2017
Name of Policy: Genetic Testing for Alzheimer s Disease Policy #: 011 Latest Review Date: May 2017 Category: Laboratory/Pathology Policy Grade: A Background/Definitions: As a general rule, benefits are
More information23 and me and you Should you test yourself for Alzheimer s and Parkinson s genes? Brain TLC November 2017
23 and me and you Should you test yourself for Alzheimer s and Parkinson s genes? Brain TLC November 2017 disclosures Dr. Quinn has no financial conflict of interest related to this topic. (eg, no financial
More informationImproving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018
Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been
More informationAlzheimer s Disease Update: From Treatment to Prevention
Alzheimer s Disease Update: From Treatment to Prevention Jeffrey M. Burns, MD Edward H. Hashinger Professor of Medicine Co-Director, KU Alzheimer s Disease Center Director, Clinical and Translational Science
More informationEuropean Prevention of Alzheimer s Dementia (EPAD)
European Prevention of Alzheimer s Dementia (EPAD) Ron Marcus, MD ISCTM Adaptive Design Workshop February 20, 2018 1 EPAD Goal The European Prevention of Alzheimer's Dementia (EPAD) project aims to develop
More informationAlzheimer s Disease Genetics: From the Bench to the Clinic
Alzheimer s Disease Genetics: From the Bench to the Clinic Celeste M. Karch, 1 Carlos Cruchaga, 1 and Alison M. Goate 1, * 1 Department of Psychiatry and Hope Center for Neurological Disorders, Washington
More informationTammie Benzinger, MD, PhD
Tammie Benzinger, MD, PhD benzingert@wustl.edu Disclosure: Tammie L.S. Benzinger, M.D., Ph.D. Research Support / Grants: NIH/NIA 5P01AG026276, 1U01AG032438, AG003991-27, 1R01NS066905-01, 1P01NS059560-01A1,
More informationADGC and NIAGADS Update October 2014 ADC Director s Meeting. Li-San Wang University of Pennsylvania
ADGC and NIAGADS Update October 2014 ADC Director s Meeting Li-San Wang University of Pennsylvania lswang@upenn.edu data@niagads.org ADGC The Alzheimer's Disease Genetics Consortium (ADGC) is funded NIA
More informationMolecular Imaging Heterogeneity of Clinically Defined AD
Molecular Imaging Heterogeneity of Clinically Defined AD Gil Rabinovici, M.D. Edward Fein & Pearl Landrith Endowed Professor UCSF Memory & Aging Center 2017 Spring ADC Meeting Boston, MA April 22, 2017
More informationCorporate Medical Policy Genetic Testing for Alzheimer s Disease
Corporate Medical Policy Genetic Testing for Alzheimer s Disease File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_alzheimers_disease 8/2010 10/2017 10/2018 10/2017
More informationAlzheimer s Biomarkers Consortium of Down Syndrome (ABC-DS)
Alzheimer s Biomarkers Consortium of Down Syndrome (ABC-DS) AN OVERVIEW (with material provided by Ben Handen & Nicole Schupf) https://www.nia.nih.gov/research/abc-ds Alzheimer s Biomarkers Consortium
More informationStephen Salloway, M.D., M.S. Disclosure of Interest
Challenges in the Early Diagnosis of Alzheimer s Disease Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University 2 nd Annual Early Alzheimer s Educational
More informationGenetic Testing for Alzheimer's Disease
Medical Policy Manual Genetic Testing, Policy No. 01 Genetic Testing for Alzheimer's Disease Next Review: February 2019 Last Review: March 2018 Effective: April 1, 2018 IMPORTANT REMINDER Medical Policies
More informationEmerging CSF and serum biomarkers in atypical dementia. Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018
Emerging CSF and serum biomarkers in atypical dementia Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018 Biomarkers A characteristic that is objectively measured and evaluated as
More informationDietary Supplements, Caffeine, and Cognitive Aging
Institute of Medicine Committee on the Public Health Dimensions of the National Academies Beckman Center of the National Academies Irvine, CA June 9, 2014 Dietary Supplements, Caffeine, and Cognitive Aging
More informationClinical Genetics & Dementia
Clinical Genetics & Dementia Dr Nayana Lahiri Consultant in Clinical Genetics & Honorary Senior Lecturer Nayana.lahiri@nhs.net Aims of the Session To appreciate the potential utility of family history
More informationDISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT
Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia DISCLOSURES NONE TO REPORT Freddi Segal Gidan, PA, PhD USC Keck School of Medicine Rancho/USC California Alzheimers Disease
More informationForm D1: Clinician Diagnosis
Initial Visit Packet Form D: Clinician Diagnosis NACC Uniform Data Set (UDS) ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by the clinician.
More informationNIH Alzheimer s Disease Centers Panel Recommendations
NIH Alzheimer s Disease Centers Panel Recommendations In June, 2017 NIA engaged leading experts from academia, industry and non-profit foundations, working in Alzheimer s and other complex diseases, in
More informationADNI Experience on Developing Biomarker Tools as Example of An Approach to Catalyzing Dry AMD Drug Development
ADNI Experience on Developing Biomarker Tools as Example of An Approach to Catalyzing Dry AMD Drug Development Wm Z Potter, MD, PhD Sr. Advisor, NIMH IOM, Nov 15, 2014 Disclosures Former employee of Lilly
More informationPolygenic risk of Alzheimer disease is associated with early- and late-life processes
Polygenic risk of Alzheimer disease is associated with early- and late-life processes Elizabeth C. Mormino, PhD Reisa A. Sperling, MD Avram J. Holmes, PhD Randy L. Buckner, PhD Philip L. De Jager, MD,
More informationImaging of Alzheimer s Disease: State of the Art
July 2015 Imaging of Alzheimer s Disease: State of the Art Neir Eshel, Harvard Medical School Year IV Outline Our patient Definition of dementia Alzheimer s disease Epidemiology Diagnosis Stages of progression
More informationDoing more with genetics: Gene-environment interactions
2016 Alzheimer Disease Centers Clinical Core Leaders Meeting Doing more with genetics: Gene-environment interactions Haydeh Payami, PhD On behalf of NeuroGenetics Research Consortium (NGRC) From: Joseph
More informationLate-Onset Alzheimer s Disease Genes and the Potentially Implicated Pathways
Curr Genet Med Rep (2014) 2:85 101 DOI 10.1007/s40142-014-0034-x HOT TOPIC Late-Onset Alzheimer s Disease Genes and the Potentially Implicated Pathways Samantha L. Rosenthal M. Ilyas Kamboh Published online:
More informationMild Cognitive Impairment (MCI)
October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine
More informationA New Genetic Test for Alzheimer s Disease and Dementia Risk with transformational potential
A New Genetic Test for Alzheimer s Disease and Dementia Risk with transformational potential A Polygenic Risk Score test for Alzheimer s Disease variatect TM and SNPfitR TM provide an accurate genetic
More informationRe: Request for Information: Updating the Alzheimer s Disease-Related Dementias Research Priorities
Public Policy Division 202.393.7737 p 1212 New York Ave NW 866.865.0270 f Suite 800 www.alz.org Washington, DC 20005 Roderick Corriveau, Ph.D. Program Director National Institute of Neurological Disorders
More informationRESEARCH AND PRACTICE IN ALZHEIMER S DISEASE VOL 10 EADC OVERVIEW B. VELLAS & E. REYNISH
EADC BRUNO VELLAS 14/01/05 10:14 Page 1 EADC OVERVIEW B. VELLAS & E. REYNISH (Toulouse, France, EU) Bruno Vellas: The European Alzheimer's Disease Consortium is a European funded network of centres of
More informationFDA Perspective on Disease Modification in Schizophrenia
FDA Perspective on Disease Modification in Schizophrenia Robert Levin, M.D. Clinical Team Leader Division of Psychiatry Products Food and Drug Administration Goals and Expectations Develop treatments that
More informationCSF Aβ1-42 predicts cognitive impairment in de novo PD patients
CSF Aβ1-42 predicts cognitive impairment in de novo PD patients Mark Terrelonge MPH *1, Karen Marder MD MPH 1, Daniel Weintraub MD 2, Roy Alcalay MD MS 1 1 Columbia University Department of Neurology 2
More informationAlzheimer s Association: Public Health Perspectives & Initiatives
Alzheimer s Association: Public Health Perspectives & Initiatives Maria C. Carrillo, Ph.D. Chief Science Officer Disclosures: Full time employee of the Alzheimer s Association 2 Outline Prevalence vs Incidence
More informationDepression: An Important Risk Factor for Cognitive Decline
Depression: An Important Risk Factor for Cognitive Decline No conflicts of interest Sarah K. Tighe, M.D. Assistant Professor University of Iowa Carver College of Medicine Department of Psychiatry Institute
More informationTUESDAY, MARCH 28, 2017 WEDNESDAY, MARCH 29, 2017 WELCOME RECEPTION (VIENNA CITY HALL)
KEY: PRE CONFERENCE SYMPOSIUM SPONSORED SYMPOSIUM SYMPOSIUM PLENARY LECTURE FORUM OTHER EVENT *PRE-REGISTRATION IS REQUIRED FOR THE INFORMAL NETWORKING WITH PROFESSOR LUNCH SESSION TUESDAY, MARCH 28, 2017
More informationNIH VCID Biomarkers Consortium focused on the large unmet need for clinical trial ready VCID biomarkers with high potential for positive impact in
NIH VCID Biomarkers Consortium focused on the large unmet need for clinical trial ready VCID biomarkers with high potential for positive impact in public health Steve Greenberg*, MD, PhD, MGH (Coordinating
More informationThe Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing
The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing. (AUSTRALIAN ADNI) July 2013 UPDATE Imaging Christopher Rowe MD Neuroimaging stream leader June 2013 The Australian Imaging Biomarkers
More informationImplementation of fully automated immunoassays for CSF Aβ 1-42, t-tau and p-tau 181 in the Alzheimer s Disease Neuroimaging Initiative
Implementation of fully automated immunoassays for CSF Aβ 1-42, t-tau and p-tau 181 in the Alzheimer s Disease Neuroimaging Initiative Leslie M Shaw Perelman School of Medicine, University of Pennsylvania
More informationFinding Solutions to the Alzheimer s Disease Epidemic in Indiana: Alzheimer s Research in Indiana
Finding Solutions to the Alzheimer s Disease Epidemic in Indiana: Alzheimer s Research in Indiana Bruce Lamb, Ph.D. Executive Director Stark Neurosciences Research Institute September 13, 2017 Critical
More informationHOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE?
EAMA CORE CURRICULUM HOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE? Sofia Duque Orthogeriatric Unit São Francisco Xavier Hospital Occidental Lisbon Hospital Center University Geriatric Unit, Faculty of
More informationNIA Science Advances Update. NIA Science Advances
NIA Science Advances 2016 Update NIA Science Advances Richard J. Hodes, M.D. Director National Institute on Aging Visit from Friends of the NIA October 7, 2016 NATIONAL INSTITUES OF HEALTH National Institute
More informationNeuro degenerative PET image from FDG, amyloid to Tau
Neuro degenerative PET image from FDG, amyloid to Tau Kun Ju Lin ( ) MD, Ph.D Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital ( ) Department of Medical Imaging
More informationEarly Diagnosis of Alzheimer s Disease and MCI via Imaging and Pattern Analysis Methods. Christos Davatzikos, Ph.D.
Early Diagnosis of Alzheimer s Disease and MCI via Imaging and Pattern Analysis Methods Christos Davatzikos, Ph.D. Director, Section of Biomedical Image Analysis Professor of Radiology http://www.rad.upenn.edu/sbia
More informationChronic Effects of Neurotrauma Consortium (CENC)
Chronic Effects of Neurotrauma Consortium (CENC) 2013-2019 David X. Cifu, MD Senior TBI Specialist, U.S. Department of Veterans Affairs Associate Dean for Innovation and System Integrations, Virginia Commonwealth
More informationTitle: Pinpointing resilience in Bipolar Disorder
Title: Pinpointing resilience in Bipolar Disorder 1. AIM OF THE RESEARCH AND BRIEF BACKGROUND Bipolar disorder (BD) is a mood disorder characterised by episodes of depression and mania. It ranks as one
More informationAmyloid pathways and diseasemodifying treatments for AD: what changes are necessary in new trials? John Hardy
Amyloid pathways and diseasemodifying treatments for AD: what changes are necessary in new trials? John Hardy Reta Lila Weston Research Laboratories Department of Molecular Neuroscience UCL Institute of
More informationAlzheimer s Disease Centers meeting San Diego, CA October 14, NIA-Division of Neurosciences update"
Alzheimer s Disease Centers meeting San Diego, CA October 14, 2017 NIA-Division of Neurosciences update" Eliezer Masliah, M.D. Director, Division of Neuroscience, National Institute on Aging, NIH AD grants
More informationMRI Hippocampal Volume for Enrichment
MRI Hippocampal Volume for Enrichment Derek Hill 1,2 & Jerry Novak 3, Pat Cole 4, Diane Stephenson 5 1. IXICO plc 2. UCL, London, UK 3. Johnson and Johnson 4. Takeda 5. CAMD, Critical Path Institute 1
More informationBioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018
Press release BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018 Stockholm, Sweden, July 25, 2018 BioArctic AB (publ) (Nasdaq Stockholm:
More informationDiagnosis and Treatment of Alzhiemer s Disease
Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised
More informationComments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic Guidelines? The Debate Continues
Comments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic s? The Debate Continues Ever since new criteria came out for a research diagnosis of prodromal/preclinical
More informationRegulatory Challenges across Dementia Subtypes European View
Regulatory Challenges across Dementia Subtypes European View Population definition including Early disease at risk Endpoints in POC studies Endpoints in pivotal trials 1 Disclaimer No CoI The opinions
More informationRequest for Applications Post-Traumatic Stress Disorder GWAS
Request for Applications Post-Traumatic Stress Disorder GWAS PROGRAM OVERVIEW Cohen Veterans Bioscience & The Stanley Center for Psychiatric Research at the Broad Institute Collaboration are supporting
More informationTUESDAY, MARCH 26, 2019 WEDNESDAY, MARCH 27, 2019
KEY: PRE CONFERENCE SYMPOSIUM SPONSORED SYMPOSIUM SYMPOSIUM PLENARY LECTURE FORUM OTHER EVENT *PRE-REGISTRATION IS REQUIRED FOR THE INFORMAL NETWORKING WITH PROFESSOR LUNCH SESSION TUESDAY, MARCH 26, 2019
More informationChanging diagnostic criteria for AD - Impact on Clinical trials
Changing diagnostic criteria for AD - Impact on Clinical trials London, November 2014 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière Hospital
More informationTUESDAY, MARCH 26, 2019 WEDNESDAY, MARCH 27, 2019
KEY: PRE CONFERENCE SYMPOSIUM SPONSORED SYMPOSIUM SYMPOSIUM PLENARY LECTURE FORUM OTHER EVENT *PRE-REGISTRATION IS REQUIRED FOR THE INFORMAL NETWORKING WITH PROFESSOR LUNCH SESSION TUESDAY, MARCH 26, 2019
More informationHow can the new diagnostic criteria improve patient selection for DM therapy trials
How can the new diagnostic criteria improve patient selection for DM therapy trials Amsterdam, August 2015 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM)
More informationThe challenge of preventing Alzheimer s disease: the BBRC experience. Dr. José Luis Molinuevo
The challenge of preventing Alzheimer s disease: the BBRC experience Dr. José Luis Molinuevo Disclosures José Luis Molinuevo has provided scientific advice, been data-monitoring board member or symposium
More informationLongitudinal 148-Week Update of ANAVEX 2-73 Phase 2a Alzheimer s Disease Extension Study
Longitudinal 148-Week Update of ANAVEX 2-73 Phase 2a Alzheimer s Disease Extension Study CTAD October 2018 Harald Hampel, MD, PhD 1, Mohammad Afshar, MD, PhD 2, Frédéric Parmentier, PhD 2, Coralie Williams,
More informationDementia, Cognitive Aging Services and Support
Dementia, Cognitive Aging Services and Support Ronald C. Petersen, Ph.D., M.D. Professor of Neurology Mayo Clinic College of Medicine Rochester, MN NASUAD Washington September 2, 2015 Disclosures Pfizer,
More informationImaging Genetics: Heritability, Linkage & Association
Imaging Genetics: Heritability, Linkage & Association David C. Glahn, PhD Olin Neuropsychiatry Research Center & Department of Psychiatry, Yale University July 17, 2011 Memory Activation & APOE ε4 Risk
More informationClinical Policy Title: Genomic tests in neurology
Clinical Policy Title: Genomic tests in neurology Clinical Policy Number: 09.01.09 Effective Date: January 1, 2016 Initial Review Date: June 16, 2015 Most Recent Review Date: September 14, 2017 Next Review
More informationAmerican Society for Experimental Neurotherapeutics - ASENT 2019 Annual Meeting. Walter E Kaufmann, MD CMO Nasdaq: AVXL March 2019
LONGITUDINAL 148-WEEK EXTENSION STUDY OF ANAVEX 2-73 FOR THE TREATMENT OF ALZHEIMER S DISEASE DEMONSTRATES MAINTAINED ACTIVITIES OF DAILY LIVING SCORE (ADCS-ADL) AND REDUCED COGNITIVE DECLINE (MMSE) FOR
More informationDo not copy or distribute without permission. S. Weintraub, CNADC, NUFSM, 2009
Sandra Weintraub, Ph.D. Clinical Core Director, Cognitive Neurology and Alzheimer s Disease Center Northwestern University Feinberg School of Medicine Chicago, Illinois Dementia: a condition caused by
More informationWashington University: Setting the Stage for Secondary Prevention Trials in Alzheimer Disease
Washington University: Setting the Stage for Secondary Prevention Trials in Alzheimer Disease John C. Morris, MD Harvey A. and Dorismae Hacker Friedman Distinguished Professor of Neurology Disclosure Statement
More informationConcept paper on no need for revision of the guideline on medicinal products for the treatment of Alzheimer's disease and other dementias
15 March 20122 EMA/CHMP/60715/2012 Committee for Medicinal Products for Human Use (CHMP) Concept paper on no need for revision of the guideline on medicinal products for the treatment of Alzheimer's disease
More informationCognitive Aging: Defining normal vs. disease?
Cognitive Aging: Defining normal vs. disease? Reisa Sperling, M.D. Harvard Aging Brain Study Center for Alzheimer Research and Treatment Brigham and Women s Hospital Massachusetts General Hospital Harvard
More informationTheme Topics Subtopics. Basic and Translational Science. Development of New Models and Analysis Methods
Basic and Translational Science Development of New Models and Analysis Methods α-synuclein Amyloid/Abeta Behavioral models Inflammation Novel assays and technologies Screening studies/platforms Seeding
More informationValutazione dei disturbi neurocognitivi e invecchiamento: non solo HAND. Workshop Nazionale CISAI Lecco 20 Marzo 2015
Valutazione dei disturbi neurocognitivi e invecchiamento: non solo HAND Workshop Nazionale CISAI Lecco 20 Marzo 2015 Paola Cinque Dipartimento di Malattie Infettive Istituto Scientifico San Raffaele, Milano
More informationNew diagnostic criteria for Alzheimer s disease and mild cognitive impairment for the practical neurologist
New diagnostic criteria for Alzheimer s disease and mild cognitive impairment for the practical neurologist Andrew E Budson, 1,2 Paul R Solomon 2,3 1 Center for Translational Cognitive Neuroscience, VA
More informationThe use of diagnostic FFPE material in cancer epidemiology research
The use of diagnostic FFPE material in cancer epidemiology research Neil O Callaghan Genetic Epidemiology Laboratory Department of Pathology The University of Melbourne www.pedigree.org.au Overview Who
More informationSupplementary Information
Supplementary Information Meta-analysis of 74,46 individuals identifies 11 new susceptibility loci for Alzheimer s disease Jean-Charles Lambert, Carla A Ibrahim-Verbaas, Denise Harold, Adam C Naj, Rebecca
More informationAlzheimer s Disease Neuroimaging Initiative
Alzheimer s Disease Neuroimaging Initiative Steering Committee Meeting April 18, 2016 Neuropathology Core John C. Morris, MD Nigel J. Cairns, PhD, FRCPath Erin Franklin, MS Table 1. Participants Autopsied
More informationDementia Update. Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota
Dementia Update Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Nothing to disclose Dementia Progressive deterioration in mental function
More informationAT RISK, SCI, EMCI: THE ALPHABET SOUP OF PRECLINICAL AND PRODROMAL ALZHEIMER DISEASE
AT RISK, SCI, EMCI: THE ALPHABET SOUP OF PRECLINICAL AND PRODROMAL ALZHEIMER DISEASE Mary Ellen Quiceno, MD, FAAN Associate Professor of Neurology Mary Quiceno, MD discloses she has received honoraria
More informationRecent publications using the NACC Database. Lilah Besser
Recent publications using the NACC Database Lilah Besser Data requests and publications Using NACC data Number of requests by year Type 2009 2010 2011 2012 2013 2014 2015 Data files* 55 85 217 174 204
More informationEngineering team: Andrew Lang, Bo Liu, Jerry Prince, Brian Caffo, Murat bilgel, Runze Tan, Chun-Guang, and Zhou Ye; Medical team: Kostas Lyketsos,
Engineering team: Andrew Lang, Bo Liu, Jerry Prince, Brian Caffo, Murat bilgel, Runze Tan, Chun-Guang, and Zhou Ye; Medical team: Kostas Lyketsos, Susan Resnik, Sterling Johnson, and Pierre Jedynak Longitudinal
More informationIl processo diagnostico dell Alzheimer dalla clinica al neuroimaging Giovanni B. Frisoni M.D.
Il processo diagnostico dell Alzheimer dalla clinica al neuroimaging Giovanni B. Frisoni M.D. Professor of Clinical Neurosciences, University of Geneva Médecin Responsable, Memory Clinic, Hôpitaux Universitaires
More informationDementia and Healthy Ageing : is the pathology any different?
Dementia and Healthy Ageing : is the pathology any different? Professor David Mann, Professor of Neuropathology, University of Manchester, Hope Hospital, Salford DEMENTIA Loss of connectivity within association
More informationAdvances in Alzheimer s diagnosis; implications for clinical practice. Wiesje M. van der Flier Alzheimer Europe Conference Berlin, 4 October 2017
Advances in Alzheimer s diagnosis; implications for clinical practice Wiesje M. van der Flier Alzheimer Europe Conference Berlin, 4 October 2017 Grand Challenge Alzheimer s disease 47 million worldwide
More informationDementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada
Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends
More informationSeptember 26 28, 2013 Westin Tampa Harbour Island. Co-sponsored by
September 26 28, 2013 Westin Tampa Harbour Island Co-sponsored by From Brains at Risk to Cognitive Dysfunction: The Role of Vascular Pathology Ralph Sacco, MD, MS, FAHA, FAAN Miller School of Medicine
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews Efficacy and safety of amyloid-beta immunotherapy for Alzheimer's disease: systematic review Marwa El-toukhy, Mohamed Zalabia, Ahmed Raslan,
More informationUSE OF BIOMARKERS TO DISTINGUISH SUBTYPES OF DEMENTIA. SGEC Webinar Handouts 1/18/2013
Please visit our website for more information http://sgec.stanford.edu/ SGEC Webinar Handouts 1/18/2013 2013 WEBINAR SERIES STATE OF THE SCIENCE: DEMENTIA EVALUATION AND MANAGEMENT AMONG DIVERSE OLDER
More informationMild Cognitive Impairment
Mild Cognitive Impairment Victor W. Henderson, MD, MS Departments of Health Research & Policy (Epidemiology) and of Neurology & Neurological Sciences Stanford University Director, Stanford Alzheimer s
More informationGraphical Modeling Approaches for Estimating Brain Networks
Graphical Modeling Approaches for Estimating Brain Networks BIOS 516 Suprateek Kundu Department of Biostatistics Emory University. September 28, 2017 Introduction My research focuses on understanding how
More informationGenome-wide association studies for human narcolepsy and other complex diseases
ETHZ-JST Joint WS Sept. 15-16, 2008 Genome-wide association studies for human narcolepsy and other complex diseases Katsushi Tokunaga Department of Human Genetics Graduate School of Medicine The University
More informationResearch Domain Criteria: What They Are and Why They Matter Stephen J. Glatt, Ph.D. Stephen V. Faraone, Ph.D.
Research Domain Criteria: What They Are and Why They Matter Stephen J. Glatt, Ph.D. Stephen V. Faraone, Ph.D. Department of Psychiatry and Behavioral Sciences, Department of Neuroscience and Physiology,
More informationMild Cognitive Impairment or Mild Neurocognitive Disorder: Implications for Clinical Practice. Hypothesized Key Players in the Pathogenesis of AD
AD is a Neurodegenerative Disease as Seen in the PET Scan and is Characterized by Amyloid Plaques and Neurofibrillary Tangles Mild Cognitive Impairment or Mild Neurocognitive Disorder: Implications for
More informationNeuropsychiatric symptoms as predictors of MCI and dementia: Epidemiologic evidence
16th Annual MCI Symposium January 20, 2018 Miami, FL Neuropsychiatric symptoms as predictors of MCI and dementia: Epidemiologic evidence Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant,
More informationHHS Public Access Author manuscript Alzheimers Dement. Author manuscript; available in PMC 2016 July 01.
Impact of the Alzheimer s Disease Neuroimaging Initiative, 2004 to 2014 Michael W. Weiner a,b,c,d,e,*, Dallas P. Veitch a, Paul S. Aisen f, Laurel A. Beckett g, Nigel J. Cairns h,i, Jesse Cedarbaum j,
More informationThe Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing
The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing. (AUSTRALIAN ADNI) July 2012 UPDATE Imaging Christopher Rowe MD Neuroimaging stream leader October 2011 The Australian Imaging Biomarkers
More informationErin Cullnan Research Assistant, University of Illinois at Chicago
Dr. Moises Gaviria Distinguished Professor of Psychiatry, University of Illinois at Chicago Director of Consultation Liaison Service, Advocate Christ Medical Center Director of the Older Adult Program,
More information